Ziprasidone, like quetiapine, has been shown to be superior to placebo for the reduction of total psychopathology and positive and negative symptoms. (1 66) There is limited evidence to suggest superiority over typical neuroleptics with regard to improvement in positive and negative symptoms. (1. 66) Ziprasidone significantly improved negative symptoms and reduced the risk of relapse compared to placebo in a 1-year maintenance study in stable hospitalized chronic schizophrenic patients.(67) The dose range of ziprasidone for acute treatment appears to be between 40 and 160 mg/day. Maintenance doses appear to be at the lower end of this range. Preliminary data on the cognitive effects of ziprasidone are encouraging. A parenteral formulation of ziprasidone has been developed which should be useful in situations where oral medication is unacceptable or more rapid action is needed. In summary, ziprasidone appears to be a useful additional atypical antipsychotic agent because of its favourable side-effect profile, including no weight gain—a major problem with olanzapine and clozapine—and no prolactin elevation, which is a less serious side-effect of risperidone.
Was this article helpful?